tbuckley/cabot-search huggingface dataset:
THE EMPLOYMENT OF X RAYS FOR THE RELIEF OF SOME FORMS OF BLINDNESS.
Journal: JAMA (1897)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Medical News
Journal: JAMA (1918)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Social Medicine
Journal: JAMA (1925)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Diagnosis and Reporting of HIV and AIDS in States With Integrated HIV and AIDS Surveillance— United States, January 1994-June 1997
Journal: JAMA (1998)

Recent reports based on acquired immunodeficiency syndrome (AIDS) surveillance data have highlighted substantial declines in AIDS incidence and deaths. As a result of improvements in treatment and care of persons infected with human immunodeficiency virus (HIV), surveillance of AIDS alone no longer accurately reflects the magnitude or direction of the epidemic. Current public health and clinical recommendations promote early diagnosis and treatment of HIV disease. Data on persons in whom HIV infection is diagnosed before AIDS is diagnosed are needed to determine populations in need of prevention and treatment services. This report examines data for persons aged > or =13 years in whom HIV infection was diagnosed in 25 states that conducted name-based HIV surveillance in addition to AIDS surveillance during January 1994-June 1997. Provisional data indicate that declines in AIDS incidence in these states were not accompanied by comparable declines in the number of newly diagnosed HIV cases.
CODE OF MEDICAL ETHICS AND ETIQUETTE OF THE AMERICAN MEDICAL ASSOCIATION.Report of Majority of Committee.
Journal: JAMA (1894)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Self-regulation in hospital waiting lists
Authors: D P Smethurst, H C Williams
Journal: Journal of the Royal Society of Medicine (2002)

There is evidence that hospital waiting lists in the UK are resistant to shortening because reductions in length generate increases in referrals. We explored this concept by examining outpatient data for eight specialties in a large hospital centre over 17 months. Correlation coefficients were calculated by regressing waiting list density (numbers waiting more than 26 weeks) against referral rate. In three of the eight specialties, with the longest waiting lists, referral rates were significantly related, after one month's delay, to waiting list density (P<0.01)—dermatology, R=0.68; ear-nose-throat R=0.78; trauma/orthopaedics (R=0.64). These were the three with the longest lists. These results help to explain why initiatives to shorten waiting lists are commonly ineffective in the long term.
Abstract 315: Identification of distinct and targetable mechanisms of acquired resistance to CDK4/6 inhibitors
Authors: Stephen Parsons
Journal: Cancer Research (2019)

Abstract Recently, three CDK4/6 inhibitors were approved by FDA and became effective treatments for ER+ breast cancer patients. However, most if not all patients eventually progress on treatment . To identify mechanisms associated with acquired resistance to CDK4/6 inhibitors, we derived 15 CDK4/6i-resistant variants from human cancer cell lines highly sensitive to CDK4/6 inhibition with abemaciclib or palbociclib. Transcriptome and proteomic profiling of the derivatives revealed four general classes of alteration: decreased RB1, increased CCNE1 or CCNE2, increased ERK phosphorylation, and increased Aurora-A expression. A drug screen was employed to identify drugs or abemaciclib-drug combinations that could suppress growth of the resistant variants. Inhibitors of Aurora-A, Chk1 and the Ras-MAPK pathway were effective for the treatment of the respective classes of resistant derivative. Importantly, Rb loss, Aurora-A amplifications and Ras mutations were all observed as recurrent alterations in biopsies from ER+ breast cancer patients after progression on CDK4/6 inhibitors (1,2). Together these data demonstrate that cancer cells can escape from suppression by CDK4/6 drugs via multiple mechanisms and suggest clinically available therapeutic strategies to treat different classes of resistance. 1. S Wander et al, AACR, 2018 2. R Condorelli et al, Annals of Oncology, vol 29, issue 3, 640-645, 2017 Citation Format: Stephen Parsons. Identification of distinct and targetable mechanisms of acquired resistance to CDK4/6 inhibitors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 315.
Primary Care
Authors: James A. Burdette
Journal: JAMA (1977)

<h3>To the Editor.—</h3> Having a personal interest in the evaluation of costs and outcomes in primary care,<sup>1</sup>I read and reread the article of Wright et al (238:46-50, 1977) with interest and with difficulty in evaluation of the data. Under "Methods," they include "patients who came to the clinic with any complaint of acute illness. To me, this is a vague definition without some examples of problems included and excluded. Since a comparison of costs generated by five different groups of providers is made, I wonder if comparable percentages of various problems were treated by each group of providers. For example, could most of the viral upper respiratory infections have been seen by first-year residents and most of the fractures seen by faculty? I am perplexed by the high percentage of patients with acute problems with bad outcomes (almost 25% for the whole study). It would be my expectation
Reply†
Authors: Ian N. Hines
Journal: Hepatology (2010)

We would like to thank Dr. Alisi and colleagues for their interest in our recent manuscript detailing the relationship between Kupffer cell-derived interleukin 12 (IL12) production and loss of hepatic natural killer T (NKT) cells in the steatotic liver.1 It is clear from our study and several others that NKT cells are highly sensitive to hepatic lipid accumulation, a process which we can link to IL12 production by Kupffer cells.1-4 In response to their first comment, we expected that if NKT cells were restored, hepatic lipid accumulation would also be reduced; we were very surprised to see otherwise. Indeed, these results in this model of nonalcoholic fatty liver suggest that NKT cell depletion is a consequence of lipid accumulation and Kupffer cell activation, which challenges the notion that they function to suppress hepatocellular lipid accumulation in nonalcoholic fatty liver disease. As for the mechanism(s) governing IL12 production by Kupffer cells in the nonalcoholic fatty liver, a number of potential possibilities exist with gut-liver interactions being a strong candidate. There is no doubt that gut-derived factors, including gut-derived lipopolysaccharide, contribute to Kupffer cell activation and IL12 production. Recent studies by Ma and colleagues have demonstrated the ability of probiotics, which likely alter gut microbial populations, to protect the hepatic NKT cells within the steatotic liver.5 In addition, it has been shown that Toll-like receptor-9 engagement can promote Kupffer cell-dependent and IL12-dependent NKT cell recruitment to the nonsteatotic liver and exacerbate concanavalin A-mediated hepatitis.6 This highlights the potential impact of gut-derived factors, including bacterial DNA, as key regulators of NKT cell function, although their direct influence on NKT cells within the steatotic liver remains to be determined. It is very likely that a combination of hepatocellular lipid accumulation and Kupffer cell activation promote this response. This complex association is evidenced by data from our study where isolated Kupffer cells from the steatotic liver do not produce more IL12 than those Kupffer cells isolated from a normal liver when activated in vitro, despite showing large and significant increases in its production when activated by lipopolysaccharide in vivo.1 Thus, multiple levels of regulation likely exist and gut-derived antigens no doubt contribute at least in part to this process. Current studies are directed at better understanding the mechanism(s) of Kupffer cell activation and IL12 production, as well as the potential contribution of gut-derived factors in this model of nonalcoholic fatty liver disease. Ian N. Hines Ph.D.*, * Department of Medicine, Division of Gastroenterology and Hepatology, University of North Carolina, Chapel Hill, NC.
Nicardipine as antihypertensive therapy in liver transplant recipients: Results of long-term use
Authors: C Duvoux
Journal: Hepatology (1997)

Arterial hypertension is frequent in liver transplant recipients on cyclosporine A (CsA). Nicardipine is a calcium channel blocker (CCB) that has been shown to be efficient in controlling postoperative hypertension. However, its use has been limited in organ recipients because of its reported interaction with CsA metabolism. In this report, we studied the results of the long-term use of nicardipine after liver transplantation. Forty-nine consecutive liver transplant recipients with a follow-up longer than 2 years were studied. Immunosuppressive regimen was based on CsA and prednisone. Patients with immediate postoperative hypertension received intravenous nicardipine, secondarily switched to oral nicardipine (group 1, n = 27). Patients with delayed hypertension (i.e., >2 weeks posttransplant) received other antihypertensive drugs which did not interact with CsA metabolism. These patients and those without hypertension formed group 2 (n = 22). The two groups were similar for age, sex, body weight, and transplantation indications. Interaction of nicardipine with CsA metabolism was confirmed. Whereas cyclosporine blood levels were similar in both groups at any time during the study, the mean cyclosporine daily dose required to achieve such levels was 30% lower in group 1 compared with group 2 (P < .01). This resulted in a significant cost-containment. The use of nicardipine was not associated with an increased incidence of graft rejection or CsA toxicity episodes. The results in liver transplant recipients showed that nicardipine interacts with CsA metabolism, leading to a 30% reduction in CsA dose and does not increase the risk of CsA toxicity or graft rejection. Nicardipine can be used safely for the treatment of arterial hypertension after liver transplantation with a potential cost-containment.
FDA's Hayes begins academic post
Journal: JAMA (1983)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
PARIS
Journal: JAMA (1942)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
DENMARK
Journal: JAMA (1962)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A randomized, open label, multicenter phase 2 study, to evaluate the efficacy of sorafenib (So) in patients (pts) with metastatic renal cell carcinoma (mRCC) after a radical resection of the metastases: RESORT trial.
Authors: Giuseppe Procopio, Francesco Cognetti, Rosalba Miceli, Michele Milella, Alessandra Mosca, Vincenzo Emanuele Chiuri, Alessandra Bearz, Franco Morelli, Cinzia Ortega, Francesco Atzori, Maddalena Donini, Raffaele Ratta, Antonia Martinetti, Rosanna Montone, Filippo G. De Braud, Vera Cappelletti, Elena Verzoni
Journal: Journal of Clinical Oncology (2018)

4502 Background: Radical metastasectomy (Mtx) followed by observation (Obs) is a commonly used strategy in selected mRCC pts. RESORT was the largest prospective study that assessed the role of angiogenesis inhibition in mRCC pts after radical Mtx. Methods: The main eligibility criteria were a previous nephrectomy, predominant clear cell histology, a radical excision of no more than 3 metastases. All pts were randomized (1:1) within 12 weeks (wks) from surgery to receive SO or Obs for a maximum of 52 wks with stratification according to time from nephrectomy to metastases (more vs less than 12 months-mos), site of disease (lung vs others) and number of lesions (single vs multiple). SO was administered at the standard dose 400 mg twice daily. Radiologic restaging was performed every 12 wks. The primary endpoint was recurrence-free survival (RFS), defined as the time from randomization to disease relapse or death. A blood sample for exploratory analysis was collected at defined timepoints. Results: From November 2012 to November 2017, 76 pts were enrolled (32 in SO and 36 in Obs arm); 6 pts were screening failure and 2 pts never started treatment. An interim analysis was performed in the Intention To Treat population (median follow-up 21 mos) included 68 pts with well balanced baseline characteristics between the two arms. Median RFS was 29 mos (95%CI 10-NA) in SO arm versus 35 mos (95% 17-NA) in the Obs arm: 12 and 24 mos RFS was 62% (95% CI 46-84) and 52% (95% CI 35-76) in SO while 74% (95% CI 59-91) and 59% (95% CI 42-82) in Obs arm respectively. No differences in RFS were observed considering the stratification factors. Grade 3 adverse events with SO were 22% vs 3% in the Obs arm. Only 2 pts received the full SO dose, the remaining 30 pts had at least one interruption or dose reduction. Considering the % of administered vs planned dose as a continuous variable in a Cox model, a slight decrease of the recurrence risk was observed when increasing SO dose, however the number of events observed was too small to obtain reliable estimates. Conclusions: Sorafenib was safe but did not affect RFS in pts with mRCC after complete Mtx. Clinical trial information: NCT01444807.
Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting β<sub>2</sub>agonist: observational matched cohort study (PATHOS)
Journal: BMJ (2013)

Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting β 2 agonist: observational matched cohort study (PATHOS)
Measurement of mitral valve orifice area by real-time three-dimensional ultrasound system without reconstruction process Makoto Matsumura, Ryozo Omoto, Shunei Kyo, Chigiru Kanoh, Tsuyoshi Mochizuki, Mutsuhiro Akahane. Saitama Medical School, Moroyama, Japan
Journal: Journal of the American College of Cardiology (2001)
X-linked mental deficiency megalotestes syndrome
Authors: R. H. Ruvalcaba
Journal: JAMA (1977)

Members of two kindreds had mental deficiency and megalotestes. The familial occurrence suggests an X-linked recessive trait or autosomal-dominant trait with male sex limitation. The increased testicular size was apparently due to excess fluid content. (<i>JAMA</i>238:1646-1650, 1977)
The resuscitation of near-drowning victims
Authors: J. P. Ornato
Journal: JAMA (1986)

DROWNING causes almost 9000 deaths in the United States each year out of an estimated 80 000 near-drowning incidents.<sup>1</sup>Males between the ages of 10 and 19 years are the most common victims. Fortunately, only about one of every nine or ten underwater submersion accidents results in death. When death occurs, the term "drowning" is applied. "Near-drowning" is the term used when there is at least temporary survival from suffocation by submersion.<sup>2</sup> The usual sequence of events in the animal model of drowning is initial breath holding followed by the swallowing of large amounts of water, vomiting, terminal gasping with flooding of the lungs, and death.<sup>3</sup>Animal models of near-drowning in the laboratory do not precisely mimic human drowning in natural waters.<sup>4-6</sup>This must be taken into account when extrapolating results of animal research to clinical resuscitation. Less hemodilution is noted in humans than in animals,